Baum returns as Mirati CEO as Meek departs

Mirati Therapeutics Inc. (NASDAQ:MRTX) announced that CEO David Meek would be stepping down two years after taking on the role. Founder and President Charles Baum will move back into the CEO role on an interim basis while the company looks for a permanent replacement. The announcement came as the company plans its next steps for KRAS inhibitor Krazati adagrasib, supported by a freshly raised $300 million follow-on financing.

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) hired Beth Shafer as CBO. Shafer was VP and head of R&D business development, gastrointestinal & inflammation, neuroscience, drug discovery sciences, externalizations at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). ...